Diazepam (DZP) suppositories are widely used in infants suffering from febrile convulsions. Previous studies of clinical applications of rectal DZP have shown that intermittent administration of DZP suppositories during the febrile period prevents recurrent febrile convulsions. [1] [2] [3] [4] In addition to DZP suppository, acetaminophen (AAP) suppositories are occasionally used to ease suffering by high fever. 5) However, the simultaneous combination of DZP and AAP suppositories has been reported to reduce the plasma concentration of DZP in infants with recurrent febrile convulsions.
protocol was conducted according to the Guidelines of the Ethics Review Committee for Animal Experimentation of Ehime University School of Medicine.
Preparation of Suppository
In the present studies, we prepared three kinds of suppositories: DZP suppository, with a base of PEG, PEG suppository, which has a water-soluble base and witepsol (WTS) suppository, which has an oleaginous base. DZP suppository was prepared as follows: DZP was suspended in the suppository base (a mixture containing PEG 1540 and 4000 in proportions of 1 : 1) at 60°C for 5 min. The heating condition did not reduce the DZP concentration (100.5%, nϭ3). The molten masses were immediately sucked up with a polyethylene injection syringe (4 mm inside diameter, Terumo Co., Ltd.). The suppositories were cooled at room temperature and kept at 4°C until use.
Pharmacokinetic Study in Rats After insertion of 5 mg/kg DZP suppository with or without WTS suppository into the rectum simultaneously, the anus was closed with an adhesion with Aron Alpha ® to prevent leakage. 8) Blood samples were withdrawn from a jugular vein into a heparinized catheter with the Auto Blood Sampling System (DR-II, EICOM Co., Ltd., Kyoto, Japan) at 0, 15, 30, 45 min, 1, 1.5, 2, 3, 4 and 5 h after rectal administration. Blood samples were centrifuged for 15 min at 3000 rpm (5°C) and the separated plasma was stored at Ϫ20°C until analysis.
Analytical Methods Sample extraction procedures were modified Yanaihara et al. procedures 9) as follows: YMC Dispo SPE columns (100 mg/1 ml, C 18, YMC Co., Ltd., Kyoto, Japan) were positioned on the Extraction Manifolds (Waters Co., Ltd., Tokyo, Japan). Each column was prewashed twice with 1 ml of methanol, followed by a 1 ml of distilled water. For extraction, 100 ml of plasma sample, 100 ml of internal standard solution (fludiazepam, 250 ng/ml) and 100 ml-distilled water were applied to the column, and then drawn through the column in a vacuum. The column was then washed twice with 1 ml of distilled water, followed by 50 ml of acetonitrile. A collection tube was placed under To clarify the drug-base interaction between diazepam (DZP) suppository and oleaginous base, we investigated the effect of simultaneous combination of oleaginous base on the absorption and on the anticonvulsant effect of DZP Suppository in rats. Simultaneous insertion of DZP suppository and oleaginous base significantly decreased maximum concentration (C max ) and area under the blood concentration-time curve (AUC) of plasma DZP concentrations. Administration of DZP suppositories (2.5, 5 mg/kg) dose-dependently suppressed the pentylenetetrazol (PTZ)-induced seizures, and the anticonvulsant effect of DZP suppository (5 mg/kg) was reduced by simultaneous insertion of oleaginous base. In an in vitro study using a suppository release apparatus, simultaneous combination of DZP suppository and oleaginous base (1.5-98 mg) significantly decreased the accumulative release of DZP in a dose-dependent manner. These results suggested that when DZP suppository and oleaginous base are inserted simultaneously, the released DZP distributes partially to the oleaginous base, and this phenomenon is related to the decreases in the plasma concentration and the anticonvulsant effect of DZP.
each extraction column for drug elution. Five hundred microliters of acetonitrile was added to each column, and then eluted in a vacuum. To complete the elution, 500 ml of acetonitrile were added to each column. The eluent was evaporated to dryness at 40°C under a gentle stream of nitrogen for 15 min. The residue was reconstituted in 100 ml of methanol, and 50 ml was injected into the chromatograph. The calibration curve for determining plasma DZP was linear at the concentration of 10-500 ng/ml (R 2 ϭ0.99). A high-performance liquid chromatograph (LC-10AD) equipped with variable-wavelength UV detector (SPD-10AV VP ), column oven (CTO-10A), automatic injector (SIL-10A XL ) and data processor (C-R7A plus) was used (all apparatus was obtained from Shimadzu Co., Ltd., Kyoto, Japan). A reverse phase column (YMC-Pack Pro C 18, 150ϫ4.5 mm I.D. S-5 mm, 120 A, YMC Co., Ltd., Kyoto, Japan) was maintained at 40°C. The mobile phase was a mixture of acetonitrile/ water (40 : 60, v/v), and the flow rate was 1.5 ml/min. The detection was performed at 245 nm (0.002 AUFS).
Pentylenetetrazol-Induced Seizures Four groups of animals were established for the experiment of PTZ-induced seizures: PEG suppository (group 1), DZP suppository 2.5 mg/kg (group 2), DZP suppository 5 mg/kg (group 3), simultaneous insertion of DZP suppository (5 mg/kg) and WTS suppository (group 4). PEG and WTS suppositories were administered using the same volume/body weight as for DZP suppository. PTZ (100 mg/kg) was administered intraperitoneally (i.p.) 30 min after insertion of suppositories and behavioral changes were observed for 30 min. The incidence of clonic convulsion (CL) and the latency for the first CL appearance were used as indices of anticonvulsant effect. The incidence of CL calculated as shown in the following equation: CL incidence (%)ϭnumber of rats developed CL/total number of rats ϫ100. When the latency was more than 300 s, the latency was judged to be 300 s.
Release of Diazepam from Suppository An apparatus for the measurement of drug release from suppositories, model TMS-103 (Toyama Sangyo Co., Ltd., Osaka, Japan) was used according to the procedure reported by Muranishi et al. 10) Saline (300 ml, 37°C) was used as the release medium. A Durapore ® membrane filter, HVLP 04700 (diameter; 47 mm, pore size; 0.45 mm, Millipore Co., Ltd., Tokyo, Japan), was used.
11) The rotation rate of steel rod and magnetic stirrer were 25 rpm at cell phase and 95Ϯ5 rpm at release phase, respectively. Each suppository, DZP suppository (1.5 mg) with or without WTS suppository (1.5, 98, 245, or 490 mg), was entered in the cell phase. Samples (each of 3 ml) were taken from the release phase at 0, 15, 30, and 45 min, and 1, 1.5, 2, 3, 4, 5, 6, 7 and 8 h after administration of suppositories, and saline (3 ml) was added to the cell phase immediately after each sampling. The released amounts of drug from suppositories were determined spectrophotometrically for DZP at 230 nm.
Data Analysis Pharmacokinetic parameters were calculated from the DZP plasma concentration-time data for each animal using a computer program for moment analysis. 12) Statistical evaluation for the pharmacokinetic parameters was performed using the Student's t-test. The latency of CL by PTZ was analyzed using one-way analysis of variance (ANOVA) followed by Dunnett's test. The incidence of CL was assessed for significance by the Chi-squared test for independence. The percentage of accumulative release of DZP was analyzed using repeated two-way ANOVA followed by Tukey's test. All mean values of the data were presented with their standard error (S.E.). The criterion for statistical significance was set at pϽ0.05. Figure 1 shows the average plasma DZP concentrationtime profile of DZP suppository. In the control rats given 5 mg/kg of DZP rectally, the plasma concentration of DZP reached maximum after about 30 min, and then gradually decreased to a level Ͻ20 ng/ml by 4 h after administration. In rats given simultaneous insertion of DZP (5 mg/kg) and WTS suppositories, the plasma concentrations were markedly lower than in the controls. The pharmacokinetics analysis indicated that the AUC 0-1 , AUC 0-∞ and C max values were significantly lower in the combination group of suppositories compared with DZP suppository alone group. But there was no significant difference in time to reach the maximum concentration (T max ) value (Table 1 ). Figure 2 shows the incidence of CL (A) and the latency for the first CL appearance (B) induced by PTZ (100 mg/kg, i.p.) in rats, respectively. PTZ-induced CL of all rats treated with PEG suppository. DZP suppositories (2.5, 5 mg/kg) decreased the incidence of CL dose-dependently, and there was a significant difference (pϽ0.01) between 5 mg/kg DZP and PEG suppositories. The inhibitory effect of DZP suppository (5 mg/kg) was significantly suppressed by simultaneous insertion of WTS suppository and the incidence of CL was equivalent to insertion of 2.5 mg/kg DZP suppository.
RESULTS
The latency of the first CL was prolonged by insertion of DZP suppositories (2.5, 5 mg/kg) dose-dependently, and there was a significant difference (pϽ0.01) between 5 mg/kg DZP and PEG suppositories. The increase in latency at a dose of 5 mg/kg was suppressed by simultaneous insertion of WTS suppository to the same degree as 2.5 mg/kg DZP suppository. Figure 3 shows the percentage of accumulative release of DZP from suppository using a suppository release apparatus. The percentage of accumulative release increased until 8 h, and DZP suppository alone was 56% at 8 h. When WTS suppository was administered simultaneously at doses of 1.5, 98, 245 and 490 mg, the percentages of accumulative release of DZP were 34, 17.9, 17.7 and 16% at 8 h, respectively. To evaluate the effect of simultaneous administration of WTS suppository, a repeated two-way ANOVA was applied to four doses of WTS suppository compared with the DZP suppository alone. There were significant differences in the percentage of accumulative release of DZP between four doses and DZP suppository alone. The post hoc comparisons using Tukey's test showed significant differences between four doses at all time examined in this study and DZP suppository alone. Simultaneous administration of DZP suppository with WTS suppositories (1.5-98 mg) decreased the rate of release dependent on the dose of oleaginous base.
DISCUSSION
Benzodiazepines (BZPs) are widely used because of their multiple actions: sedative, anxiolytic, hypnotic, muscle relaxant and anticonvulsant. 13) Previous studies have shown the drug-drug interaction between BZPs and CYP3A4 inhibitors. For example, azole antifungals and human immunodeficiency virus (HIV) protease inhibitors increase the blood concentration of BZPs, for example midazolam and triazolam, which are mainly metabolized by CYP3A4. [14] [15] [16] On the other hand, drugs in a suppository must be released into the rectal fluid in order to reach systemic circulation. The release rates of drugs from suppositories are influenced by bases and the water solubility of the drugs. 17) Therefore, the selection of a physicochemically suitable base for the drug is essential for the preparation of the suppositories, and it is proposed that simultaneous insertion of two kinds of suppositories may cause drug-base interaction.
Previous study has shown that the combination of morphine suppository and indomethacin suppository prepared with a water-soluble base reduce the plasma concentration of morphine.
18) It is speculated that the rectal fluid is used for a water-soluble base dissolution of indomethacin suppository, and result in insufficient morphine dissolution. Thus, in this study, we investigated effect of simultaneous combination of DZP suppository and oleaginous base, and compared with the action of DZP suppository alone.
The simultaneous insertion of a DZP suppository prepared with a water-soluble base and an AAP suppository prepared with an oleaginous base has been reported to reduce the plasma concentration of DZP in infants with febrile convulsion. 6, 7) However, it was not clear whether AAP or the oleaginous base caused this phenomenon. In the present pharmacokinetic study using rats, simultaneous insertion of DZP suppository and oleaginous base decreased the C max and AUC, but not T max , consistent with the previous clinical reports. In addition, the simultaneous insertion of DZP suppository and oleaginous base attenuated the anticonvulsant effect of DZP suppository in rats. Therefore, the results of current study suggested that the decrease of serum DZP concentration in combination with DZP and AAP suppositories is due to the AAP suppository containing WTS of oleaginous base.
Generally, there are several possible explanations for the decrease in the blood concentrations after rectal administration of suppositories. First, this reducing phenomenon may result from changes in absorption of drugs via the membrane permeability of the rectum. Nonsteroidal anti-inflammatory drugs (NSAIDs), indomethacin, diclofenac sodium and as- pirin, have conversely been reported to enhance the rectal membrane permeability to drugs in rats. 19, 20) Similarly, there is an example in which the rectal membrane permeability was changed by the medicine, but in this case the plasma DZP concentration was decreased by simultaneous insertion of DZP and WTS suppositories. Another possible explanation for the decrease of plasma DZP concentration may be due to the increased drug clearance by the induction of metabolizing enzyme. However, WTS suppository of oleaginous base has not been reported to affect the membrane permeability of the rectum or the metabolism of drugs. The final possible explanation is a decrease in absorption of drugs via suppression of the release rate from the base. In the present in vitro study using a suppository release apparatus, simultaneous combination of DZP suppository and WTS suppository of oleaginous base significantly decreased the accumulative release of DZP dependent on the dose of oleaginous base (1.5-98 mg). The suppository prepared with water-soluble base is liquefied by the rectal fluid, and DZP, which is a high lipophilic drug (distribution coefficient; 1-octanol/pH 7.2 phosphate bufferϭ382), is released into the rectal fluid. These results suggested that a part of the released DZP was distributed to the oleaginous base.
In conclusion, the results of the current study indicate when DZP suppository and oleaginous base are inserted simultaneously, a part of the DZP released from the suppository is distributed to the oleaginous base, which had fused in the rectal cavity. This process leads to decreases in the plasma concentration and the anticonvulsant effect of DZP. Thus, it is necessary to avoid inserting DZP suppository and oleaginous base simultaneously and to leave a sufficient interval after administration of DZP suppository to avoid the interaction between drugs and bases. However, further studies are needed to determine the insertion interval.
